Union Minister of State Science & Technology Dr Jitendra Singh announces India’s first indigenously developed vaccine, “CERVAVAC” for the prevention of cervical cancer. Announcing the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in presence of Adar C. Poonawalla, CEO, Serum Institute of India, Pune and other prominent scientists and dignitaries, he said, this affordable and cost- effective vaccine marks an important day for DBT and BIRAC as it takes India a step closer to PM Modi’s vision of Atmanirbhar Bharat.
Dr Jitendra Singh pointed out that Cervical cancer ranks as the 2nd most prevalent cancers in India and accounts for nearly one-fourth of the world’s cervical cancer deaths despite being largely preventable. He said, current estimates indicate that every year approximately 1.25 lakhs women are diagnosed with cervical cancer, and over 75 thousand die from the disease in India, and 83 % of invasive cervical cancers are attributed to HPVs 16 or 18 in India, and 70% of cases worldwide.
The Minister said, the most promising intervention for preventing cervical cancer is vaccination against human papillomavirus (HPV). It is estimated that HPV types 16 and 18 (HPV-16 and HPV-18) together contribute to approximately 70% of all invasive cervical cancer cases worldwide.
Dr Jitendra Singh pointed out that COVID has awakened us to the virtues of preventive healthcare, particularly in a society like India having less awareness of preventive Medicare due to various socio-economic factors. He said, thanks to schemes like Ayushman, which allowed the poor, lower section of the society and the vulnerable population to indulge in the luxury of preventive medicine and preventive healthcare by getting insurance coverage of up to Rs 5 lakh.
